INTERGRATED DIA.H DL 025 - Asset Resilience Ratio
INTERGRATED DIA.H DL 025 (8I8) has an Asset Resilience Ratio of 7.34% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how INTERGRATED DIA.H DL 025's Asset Resilience Ratio has changed over time. See financial agility of INTERGRATED DIA.H DL 025 to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down INTERGRATED DIA.H DL 025's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see INTERGRATED DIA.H DL 025 (8I8) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €497.04 Million | 7.34% |
| Total Liquid Assets | €497.04 Million | 7.34% |
Asset Resilience Insights
- Limited Liquidity: INTERGRATED DIA.H DL 025 maintains only 7.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
INTERGRATED DIA.H DL 025 Industry Peers by Asset Resilience Ratio
Compare INTERGRATED DIA.H DL 025's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
Annual Asset Resilience Ratio for INTERGRATED DIA.H DL 025 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for INTERGRATED DIA.H DL 025.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.29% | €454.29 Million ≈ $531.11 Million |
€8.60 Billion ≈ $10.05 Billion |
-2.63pp |
| 2024-12-31 | 7.91% | €563.99 Million ≈ $659.36 Million |
€7.13 Billion ≈ $8.33 Billion |
+4.68pp |
| 2023-12-31 | 3.23% | €186.25 Million ≈ $217.75 Million |
€5.77 Billion ≈ $6.75 Billion |
+0.07pp |
| 2022-12-31 | 3.16% | €167.40 Million ≈ $195.71 Million |
€5.30 Billion ≈ $6.19 Billion |
-20.23pp |
| 2021-12-31 | 23.39% | €1.46 Billion ≈ $1.71 Billion |
€6.24 Billion ≈ $7.29 Billion |
-- |
About INTERGRATED DIA.H DL 025
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more